Company Overview and News
Ingersoll-Rand plc (IR - Free Report) has announced that it is offering twin rewards for shareholders in forms of share buyback authorization and quarterly dividends. These rewards have been approved by the company’s board of directors. We believe that such disbursements reflect Ingersoll-Rand’s strong cash position and commitment of rewarding shareholders handsomely. Details of Share Buyback & Quarterly Dividend Under the aforementioned buyback authorization, Ingersoll-Rand has been allowed to repurchase shares of up to $1.
[DXPE] IR.WI DXPE CSBR AIMC IR CFX INGERRAND 500210
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Ingersoll-Rand Plc (IR - Free Report) , Endo International plc (ENDP - Free Report) , Glanbia plc (GLAPY - Free Report) and Smurfit Kappa Group plc (SMFKY - Free Report) .
IR.WI GLAPY IR SKG SMFKY ENL INGERRAND ENDP 500210
The U.S. manufacturing activity has picked up tempo as exhibited by the stellar performance of Institute for Supply Management (ISM) index in August 2018. The index increased 3.2% from July to 61.3% in August — the highest reading since 2004. This was driven by strong demand for U.S. manufacturing goods, the Tax Cuts and Jobs Act, which has helped to overcome the hurdles like supply chain bottlenecks, rising input prices, shortage of skilled labourers and global trade uncertainties.
IR.WI TWIN IR IEX INGERRAND FLS 500210
Per the latest report by Ireland’s Central Statistics Office on Sep 13, the fastest-growing economy of the European Union surged beyond expectations in the second quarter. Growth was buoyed by a steady increase in technology exports. With unemployment already near a 10-year low, the country has witnessed strength in its service sector as well as household spending.
IR.WI CY GLAPY IR SKG SMFKY ENL INGERRAND ENDP 500210
U.S. manufacturing business continues to gather steam amid tariff-related uproar rooted by President Trump and other overseas countries, including China. Per the Institute for Supply Management (ISM) survey, the Purchasing Managers Index clocked its best gain since 2004 in August this year. The remarkable expansion was primarily backed by growth in orders, production and employment.
IR.WI TWIN IR LXFR ALG INGERRAND CMCO 500210
NCI Building Systems, Inc. (NCS - Free Report) : This company that designs, engineers, manufactures, and markets metal products has seen the Zacks Consensus Estimate for its current year earnings increasing 3.6% over the last 60 days.
IR.WI GJT BLT BHPBF NCS ALL BHP IR BBL BHP INGERRAND BHPLF 500210
We believe that Ingersoll-Rand plc (IR - Free Report) is a solid choice for investors seeking exposure in the industrial machinery space. The stock, with roughly $25-billion market capitalization, has been upgraded to a Zacks Rank #1 (Strong Buy) on Aug 30. Moreover, the stock’s investment appeal is accentuated by a favorable VGM Score of B. The company delivered better-than-expected results in three out of the last four quarters, with an average positive earnings surprise of 5.
IR.WI AIMC IR B CFX INGERRAND 500210
The Invesco Zacks Mid-Cap ETF (CZA - Free Report) made its debut on 04/02/2007, and is a smart beta exchange traded fund that provides broad exposure to the Mid Cap ETFs category of the market.
IR.WI BGX ETP IR BGLF BX INGERRAND 500210 BGB
U.S. GDP growth tapped the best gain in the past four years during the April-June quarter. Solid business and consumer spending, along with growth in exports, helped drive economic growth in the country.
IR.WI HD ADES AIMC IR ALG INGERRAND 500210
Good morning. My name is Virgil and I will be your conference operator today. At this time I would like to welcome everyone to the Ingersoll Rand Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question and answer session. Thank you. Zac Nagle, Vice President of Investor Relations, you may begin your conference.
IR.WI IR INGERRAND 500210
With a diverse portfolio of industrial and commercial products, Ingersoll-Rand Plc (IR - Free Report) is a premier player in the industrial goods market. This Dublin, Ireland-based firm has a solid foundation of global brands with a leading market share in all major product lines. After the divestiture of the commercial and residential security businesses, IR has been diligently focusing on improving the efficiencies and capabilities of its core businesses.
IR.WI IR MS INGERRAND 500210
Ingersoll-Rand Plc (IR - Free Report) is scheduled to report second-quarter 2018 results on Jul 25, before the market opens. The company pulled off an average positive earnings surprise of 3.91%, over the last four quarters. Notably, in the last reported quarter, Ingersoll-Rand’s earnings of 70 cents per share surpassed the Zacks Consensus Estimate by 12.9%. The Estimate for the to-be-reported quarter is pegged at $1.
IR.WI GGG IR ATKR INGERRAND ETN 500210
June ISM manufacturing index witnessed the best gain in the four months amid trade war anxieties. This call for bets on top-ranked manufacturing stocks.
IR.WI SKUFF TACO WIRE KAMN IRET TKR ZBRA TWNK TACOW IR WRD INGERRAND DHR 500210 MO
Launched on 04/02/2007, the Invesco Zacks Mid-Cap ETF (CZA - Free Report) is a smart beta exchange traded fund offering broad exposure to the Mid Cap ETFs category of the U.S. equity market.
IR.WI BGX IR BGLF BX INGERRAND NUE 500210 BGB
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...